CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
ELIANA 试验中 Tisagenlecleucel 在复发/难治性急性淋巴细胞白血病儿童及年轻成人患者中的更多更新即将到来：统计方法学能否进一步改进？
英文原题：More Updates to Come of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial: Could the Statistical Methodology Be Further Improved?
查看英文原题
More Updates to Come of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial: Could the Statistical Methodology Be Further Improved?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
摘要
这条来源本身就没有摘要（PubMed 未提供），不是「还没翻译」。可以点最下面的「在 PubMed 查看」打开原文献页面。
论文信息
- 作者
- Tong WH、Mertens BJ
- 单位
- Wing H. Tong, MD, PhD, MSc, Department of Public Health and Primary Care (PHEG), Leiden University Medical Center, Leiden, the Netherlands, Argos Zorggroep "DrieMaasStede," Center for Specialized Geriatric Care, Schiedam, the Netherlands; and Bart J. Mertens, PhD, Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands.United States
- 文献类型
- 读者来信 · 评论
- 期刊
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology2023 May 1
- 原文标识
- PubMed 36898080 · DOI 10.1200/JCO.22.02839